Answers are grounded in this paper and cite their sources.
Clinical trials reveal that CAR T-cell therapy improves survival in hematologic malignancies, suggesting ongoing care is vital for long-term survivors.
Clinical trials and real-world evidence have established the benefit of chimeric antigen receptor (CAR) T-cell therapy to reduce progression of hematologic malignancies and, in some settings, increase overall survival. However, recent studies have highlighted that patients in long-term remission remain at risk of morbidity and nonrelapse mortality, primarily because of infections and subsequent myeloid malignancies. In addition, these patients may also be survivors of chemotherapy, radiation, and/or stem-cell transplant, with broad survivorship needs. Here, we provide a roadmap for the care of patients in long-term remission after CAR-T-cell therapies and discuss avenues for future research.
No takes yet. Share an insight, caveat, or question.
Faramand et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: